Why is Emcure Pharma falling/rising?

As of 07-Jul, Emcure Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 1,246.15, reflecting a decrease of 7.6 points or 0.61%. The stock has underperformed its sector by 0.53% today and has been on a downward trend for the last two days, resulting in a total drop of 2.73% during this period. Over the past week, the stock has decreased by 4.16%, while its performance over the past month shows a decline of 6.26%. Despite the company declaring positive results for the last three consecutive quarters, including record net sales and profits, concerns about its long-term growth potential persist, as indicated by an annual operating profit growth rate of only 8.80% over the last five years.
In the broader market context, the Sensex has shown a slight decline of 0.20% over the past week, which indicates that the overall market sentiment is relatively stable compared to Emcure's more significant drop. The stock's performance year-to-date is notably poor, with a decline of 13.34%, while the Sensex has gained 6.79% in the same period. This stark contrast highlights the challenges Emcure faces in attracting investor confidence, despite its high management efficiency and strong ability to service debt. The stock's valuation appears expensive, contributing to investor hesitance, especially given its low returns compared to the benchmark.